National Centre for Cell Science, NCCS Complex, Pune University Campus, Ganeshkhind, Pune, MH-411007, India.
J Immunother Cancer. 2019 Aug 6;7(1):208. doi: 10.1186/s40425-019-0697-7.
NKT cells play an important role in anti-tumor immunity. Alpha-galactosylceramide (α-GalCer), a synthetic glycolipid is presented to natural killer T (NKT) cells by most antigen-presenting cells through CD1d molecules leading to activation of NKT cells. However, the precise mechanisms of how α-GalCer-activated NKT regulate the polarization of the macrophages and effector T cells in the solid tumor are not studied adequately.
We induced solid tumor in C57BL/6 mice by subcutaneous injection of B16F10 cell line (1 X 10 cells) and monitored the tumor growth. Animals were given an intraperitoneal injection of α-GalCer (2 μg/injection) in 200 μl PBS on day + 1, + 5, + 10, + 15, and + 20 (with respect to tumor cell injection). Immune cells were characterized using flow cytometry and immunofluorescence staining. NK cells, Gr1 cells, and F4/80 macrophages in the mice were depleted by intravenous injection of cell-specific antibodies. Statistical analysis was performed using Student's t-test or one-way ANOVA.
Our results showed that intratumoral NKT cells have a lower frequency of CD69, CD25, CD122, and IFN-γR expression; produced less inflammatory cytokines such as IFN-γ, TNF-α, and GM-CSF; higher frequency CD62L NKT cells; and also showed reduced proliferation as compared to the splenic NKT cells. Mice treated with α-GalCer showed a significantly increased frequency of IFN-γ-producing NKT cells, CD8 T cells, and effector Th1 cells. Depletion of NK cells in α-GalCer-treated mice showed a lower frequency of IFN-γ-producing CD4 and CD8 T cells in the tumor and prevented the α-GalCer-induced tumor growth. NKT cell activation with α-GalCer treatment significantly increased the iNOSCD206 M1-macrophages and reduced the iNOSCD206 M2-macrophages in the spleen and tumor, and depletion of F4/80 macrophages prevented the α-GalCer-induced reduction in the tumor growth.
We showed that activation of NKT cell with α-GalCer modulates the frequency of M1-macrophages and effector Th1 cells in the secondary lymphoid tissues and tumor microenvironment and inhibit tumor growth. The finding suggests that activation of NKT cells with α-GalCer may provide an effective anti-cancer outcome.
自然杀伤 T(NKT)细胞在抗肿瘤免疫中发挥重要作用。α-半乳糖神经酰胺(α-GalCer)是一种合成糖脂,通过 CD1d 分子被大多数抗原呈递细胞呈递给自然杀伤 T(NKT)细胞,导致 NKT 细胞激活。然而,α-GalCer 激活的 NKT 如何调节实体瘤中巨噬细胞和效应 T 细胞的极化的精确机制尚未得到充分研究。
我们通过皮下注射 B16F10 细胞系(1×10 个细胞)在 C57BL/6 小鼠中诱导实体瘤,并监测肿瘤生长。动物在肿瘤细胞注射后第+1、+5、+10、+15 和+20 天(相对于肿瘤细胞注射)接受腹腔内注射 α-GalCer(2μg/注射)200μl PBS。使用流式细胞术和免疫荧光染色来表征免疫细胞。通过静脉内注射细胞特异性抗体耗尽小鼠中的 NK 细胞、Gr1 细胞和 F4/80 巨噬细胞。使用 Student's t 检验或单因素方差分析进行统计分析。
我们的结果表明,肿瘤内 NKT 细胞的 CD69、CD25、CD122 和 IFN-γR 表达频率较低;产生较少的炎症细胞因子,如 IFN-γ、TNF-α 和 GM-CSF;CD62L NKT 细胞频率较高;并且与脾 NKT 细胞相比,增殖能力也降低。用 α-GalCer 治疗的小鼠显示 IFN-γ 产生的 NKT 细胞、CD8 T 细胞和效应 Th1 细胞的频率显著增加。在 α-GalCer 治疗的小鼠中耗尽 NK 细胞会导致肿瘤中 IFN-γ 产生的 CD4 和 CD8 T 细胞频率降低,并阻止 α-GalCer 诱导的肿瘤生长。用 α-GalCer 激活 NKT 细胞可显著增加脾和肿瘤中 iNOSCD206 M1-巨噬细胞的数量,并减少 iNOSCD206 M2-巨噬细胞的数量,耗尽 F4/80 巨噬细胞可阻止 α-GalCer 诱导的肿瘤生长。
我们表明,用 α-GalCer 激活 NKT 细胞可调节次级淋巴组织和肿瘤微环境中 M1-巨噬细胞和效应 Th1 细胞的频率,并抑制肿瘤生长。这一发现表明,用 α-GalCer 激活 NKT 细胞可能提供有效的抗癌效果。